skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

開発中の医薬品をFDA承認確率で示すデータベース

Biomedtracker | Pharma intelligence

Biomedtracker(バイオメドトラッカー)では、アメリカの医薬品開発プロセスの動きを2003年以降独自に分析しています。弊社アナリストチームが下記に挙げる代表的なイベントと、それらによるインパクトを発生と同時に分析&評価し、アメリカ食品医薬品局(FDA)の承認確率(LOA: Likelihood of Approval)で提示します。そうすることで、医薬品の開発動向をいち早く正確に把握できるデータベースがBiomedtrackerです。

医薬品開発に大きな影響を与える代表的なイベントやカタリストの例:

  • 臨床試験の開始や結果報告
  • 学会やカンファレンスにおける発表
  • ライセンス、M&A、提携に関する活動
  • 企業発表(プレスリリース、収支報告、投資家向け情報)
  • 薬事行政の動向、など

Biomedtrackerをご利用いただくことのメリット:

公平性&即時性
第三者的立場からバイアスのないコメントを付与し、情報をほぼ即日更新します。

イベントの種類が豊富&検索可能
会社情報、特許、開発品の進捗、承認申請、臨床試験結果報告など275種類。過去のイベントは時系列で確認できます。

学会の情報収集など関連情報へのアクセス
アナリストが参加した学会のレポートを発行します(例: JP Morgan, ASCO, ASH, AAN, ATSなど)。お客様が参加することができなかった海外の学会に関する情報を収集できます。また、アメリカ食品医薬品局(FDA)諮問委員会での評価・投票結果やKOL(Key Opinion Leader)インタビュー、弊社が発行する様々なレポートにもアクセスできます。

Datamonitor Healthcareとの併用が効果的です
開発中医薬品をリアルタイムで追跡するBiomedtrackerは、医薬品の市場調査レポートライブラリーである姉妹サービスDatamonitor Healthcareとの併用が効果的です。ぜひ合わせてご検討ください。

 

【お知らせ】無料オンラインサービス説明会&トレーニングを開催します!
『開発品をFDA承認確率でみるBiomedtrackerについて』2018年10月10日(水)16時~17時、お申し込みはこちらから

このサービスの特徴

無料の最新記事&レポート

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    EU Sees Drug Shortage Risk From COVID-19 Second Wave

    A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

    Topic Coronavirus Distribution

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

    Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Remdesivir Compulsory Licensing Is A Dead End For Europe

    In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

    Topic Coronavirus Intellectual Property policy-and-regulation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Remdesivir Licensing Agreements for Generics Companies

    Keep up with crucial developments in the generics industry as Gilead signs non-exclusive, voluntary licensing agreements with several generics manufacturers in an effort to more widely manufacture and distribute the COVID-19 drug remdesivir, used to help patients recover from severe coronavirus infections faster.

    Topic drug-development-landscape

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Glenmark Debuts Favipiravir For COVID-19 In India

    Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.

    Topic Coronavirus Drug Review

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Dr Reddys Joins Remdesivir Licensees

    Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    WHO Launches COVID-19 Technology Access Pool

    C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Teva, Sandoz And Accord Take COVID-19 Action

    While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Hikma Outlines Strategy For Coping With COVID-19 Demand

    Hikma Outlines Strategy For Coping With COVID-19 Demand

    As Hikma launches propofol vials in three presentations in the US to address a local shortage, CEO Siggi Olafsson explains how the company is more broadly keeping on top of the higher demand generated by the coronavirus pandemic.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Teva, Sandoz And Accord Take COVID-19 Action

    While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    WHO Launches COVID-19 Technology Access Pool

    WHO Launches COVID-19 Technology Access Pool

    C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Sets Out Plans To Trial Coronavirus Treatments

    In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Biosimilars Conference Coverage

    Biosimilars Conference Coverage

    Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

    Topic biosimilars

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Will Trial COVID-19 Antiviral From July

    Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

    Topic Coronavirus vaccines

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Australian Bodies Set Out Joint Position On Coronavirus

    Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.

製品説明を兼ねた無料デモ&お問い合わせ

専任スタッフによる詳しい説明を兼ねた無料デモンストレーションを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。